Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

Novo Nordisk reported mostly mild side effects from its experimental weight-loss drug CagriSema, though results upset ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

How Australian pregnant women are tested for gestational diabetes is set to change, with new national guidelines released ...

Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction ...

A major milestone in pediatric healthcare was marked with the inauguration of the Changing Diabetes in Children (CDiC) Center ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...